title: Human papillomavirus immunization is associated with increased expression of different innate immune regulatory receptors.
abstract: Human papillomavirus (HPV) is able to inhibit the secretion of gamma interferon (IFN-γ) and the expression of some immune innate cell receptors. Immunoglobulin-like transcript 2 (ILT2) is a regulatory receptor that seems to participate in the pathogenesis of viral infections. We have studied the expression and function of ILT2 and the expression of other NK cell receptors in 23 healthy women before and after immunization with the quadrivalent HPV (type 6/11/16/18) vaccine (Gardasil). Receptor expression was analyzed by flow cytometry in freshly isolated peripheral blood mononuclear cells as well as after in vitro stimulation with the quadrivalent HPV (type 6/11/16/18) vaccine. In addition, the regulatory function of ILT2 on cell proliferation and IFN-γ production was analyzed. We found a significant increase in the expression of ILT2 by NK and CD3(+) CD56(+) lymphocytes and monocytes after quadrivalent HPV (type 6/11/16/18) vaccine immunization. In addition, the in vitro stimulation with the quadrivalent HPV (type 6/11/16/18) vaccine also increased the proportion of CD3(-) CD56(+) ILT2(+) NK cells. Although the inhibitory function of ILT2 on cell proliferation was enhanced after HPV immunization, the in vitro engagement of this receptor did not affect the synthesis of IFN-γ induced by HPV. Finally, a significant increase in the expression of NKG2D, NKp30, and NKp46 by NK and CD3(+) CD56(+) lymphocytes was detected after quadrivalent HPV (type 6/11/16/18) vaccine immunization. Our data indicate that HPV immunization is associated with significant changes in the expression and function of different innate immune receptors, including ILT2, which may participate in the protective effect of HPV vaccines.
authors.affiliation: Department of Immunology, School of Medicine, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
authors.forename: V
authors.initials: V
authors.lastname: Colmenares
authors.forename: D E
authors.initials: DE
authors.lastname: Noyola
authors.forename: A
authors.initials: A
authors.lastname: Monsiváis-Urenda
authors.forename: M
authors.initials: M
authors.lastname: Salgado-Bustamante
authors.forename: L
authors.initials: L
authors.lastname: Estrada-Capetillo
authors.forename: R
authors.initials: R
authors.lastname: González-Amaro
authors.forename: L
authors.initials: L
authors.lastname: Baranda
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000096:biosynthesis*; D049109:Cell Proliferation; D005260:Female; D005434:Flow Cytometry; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D007113:Immunity, Innate; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D008214:Lymphocytes / Q000276:immunology; D009000:Monocytes / Q000276:immunology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D011971:Receptors, Immunologic / Q000096:biosynthesis*; D055815:Young Adult
chemical_list: D015703:Antigens, CD; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; C105299:LILRB1 protein, human; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D053918:Papillomavirus Vaccines; D011971:Receptors, Immunologic; D007371:Interferon-gamma